Literature DB >> 26161251

Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches.

Dilip K Tosh1, Kenneth A Jacobson1.   

Abstract

Adenosine receptors (ARs) and P2Y receptors for purine and pyrimidine nucleotides have widespread distribution and regulate countless physiological processes. Various synthetic ligands are in clinical trials for treatment of inflammatory diseases, pain, cancer, thrombosis, ischemia, and other conditions. The methanocarba (bicyclo[3.1.0]hexane) ring system as a rigid substitution for ribose, which maintains either a North (N) or South (S) conformation, tends to preserve or enhance the potency and/or selectivity for certain receptor subtypes. This review summarizes recent developments in the synthetic approaches to these biologically important nucleoside and nucleotide analogues.

Entities:  

Year:  2013        PMID: 26161251      PMCID: PMC4493925          DOI: 10.1039/C2MD20348K

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  33 in total

Review 1.  Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.

Authors:  Pier Giovanni Baraldi; Delia Preti; Pier Andrea Borea; Katia Varani
Journal:  J Med Chem       Date:  2012-04-17       Impact factor: 7.446

2.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  Stereoselective synthesis of 2'-C-methyl-cyclopropyl-fused carbanucleosides as potential anti-HCV agents.

Authors:  Jeong A Lee; Hea Ok Kim; Dilip K Tosh; Hyung Ryong Moon; Sanghee Kim; Lak Shin Jeong
Journal:  Org Lett       Date:  2006-10-26       Impact factor: 6.005

5.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.

Authors:  Dilip K Tosh; Silvia Paoletta; Francesca Deflorian; Khai Phan; Steven M Moss; Zhan-Guo Gao; Xiaohui Jiang; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

6.  Synthesis of bicyclo[3.1.0]hexane derivatives as conformationally restricted analogues of beta-arabinofuranosyl and alpha-galactofuranosyl rings.

Authors:  Jing Li; Todd L Lowary
Journal:  Org Lett       Date:  2008-01-30       Impact factor: 6.005

7.  Enantioselective synthesis of bicyclo[3.1.0]hexane carbocyclic nucleosides via a lipase-catalyzed asymmetric acetylation. Characterization of an unusual acetal byproduct.

Authors:  Yuichi Yoshimura; Hyung R Moon; Yongseok Choi; Victor E Marquez
Journal:  J Org Chem       Date:  2002-08-23       Impact factor: 4.354

8.  Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Artem Melman; Ben Wang; Bhalchandra V Joshi; Zhan-Guo Gao; Sonia de Castro; Cara L Heller; Soo-Kyung Kim; Lak Shin Jeong; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2008-08-07       Impact factor: 3.641

9.  Synthesis of ethyl (1S,2R,3S,4S,5S)-2,3-O-(isopropylidene)-4-hydroxy-bicyclo[3.1.0]hexane-carboxylate from L-ribose: a versatile chiral synthon for preparation of adenosine and P2 receptor ligands.

Authors:  Bhalchandra V Joshi; Artem Melman; Richard L Mackman; Kenneth A Jacobson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-03       Impact factor: 1.381

10.  2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists.

Authors:  Hak Sung Kim; Michihiro Ohno; Bin Xu; Hea Ok Kim; Yongseok Choi; Xiao D Ji; Savitri Maddileti; Victor E Marquez; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2003-11-06       Impact factor: 7.446

View more
  5 in total

1.  Survey of ribose ring pucker of signaling nucleosides and nucleotides.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2019-08-28       Impact factor: 1.381

Review 2.  Polypharmacology of conformationally locked methanocarba nucleosides.

Authors:  Kenneth A Jacobson; Dilip K Tosh; Kiran S Toti; Antonella Ciancetta
Journal:  Drug Discov Today       Date:  2017-08-03       Impact factor: 7.851

3.  Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.

Authors:  Dilip K Tosh; Silvia Paoletta; Zhoumou Chen; Steven Crane; John Lloyd; Zhan-Guo Gao; Elizabeth T Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2015       Impact factor: 3.597

Review 4.  John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Silvia Paoletta; Evgeny Kiselev; Saibal Chakraborty; P Suresh Jayasekara; Ramachandran Balasubramanian; Dilip K Tosh
Journal:  Comput Struct Biotechnol J       Date:  2014-10-16       Impact factor: 7.271

5.  In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.

Authors:  Dilip K Tosh; Amanda Finley; Silvia Paoletta; Steven M Moss; Zhan-Guo Gao; Elizabeth T Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2014-11-25       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.